Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HEPMET-1: HCV Treatment in MMT Patients
NCT00147784Phase 3Completed
- Sponsor
- Sørlandet sykehus
- Start
- Mar 2006
- Primary completion
- Jun 2007
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of peginterferon alfa-2a and ribavirin in hepatitis C (HCV), sponsored by Sørlandet sykehus. Primary endpoint: Sustained Virological Response. Started Mar 2006; status: completed.
02
Drugs
peginterferon alfa-2aribavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00147784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00147784.